Seminars in thrombosis and hemostasis最新文献_第6页

Red Blood Cells are Critical for Hemostasis and Thrombosis. 红细胞是止血和血栓形成的关键。

IF 3.6 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2025-07-03 DOI: 10.1055/a-2640-3081

Hyunjung Kim, Katie Houck, Sam Neuffer, Jing-Fei Dong

{"title":"Red Blood Cells are Critical for Hemostasis and Thrombosis.","authors":"Hyunjung Kim, Katie Houck, Sam Neuffer, Jing-Fei Dong","doi":"10.1055/a-2640-3081","DOIUrl":"10.1055/a-2640-3081","url":null,"abstract":"Hemostasis in humans has traditionally been considered to be a function of platelets, coagulation, and the subendothelial matrix, but the role of red blood cells (RBCs) has been increasingly recognized. RBCs regulate hemostasis through biophysical and biochemical means. For the former, faster-moving RBCs in the center of vessels marginalize platelets and plasma to the vessel walls, where the platelets constantly probe the endothelial surface for injury. RBC counts also determine blood viscosity, which regulates the shear stress of laminar blood flow. For the latter, RBCs are the largest pool of adenosine triphosphate (ATP), which, upon release, is rapidly hydrolyzed to adenosine diphosphate (ADP). Both ATP and ADP activate platelets. Quantitative and qualitative abnormalities in RBCs have also been consistently identified as significant risk factors for arterial and venous thrombosis. Thrombosis is a major complication associated with diseases such as polycythemia vera, secondary erythrocytosis, and sickle cell anemia, all of which present with changes in numbers and physical properties of RBCs. Thrombosis is also common in conditions with significant hemolysis, such as paroxysmal nocturnal hemoglobinuria, severe infections, and when patients are on mechanical support. In this review, we discuss findings from clinical observations and mechanistic studies of how RBCs regulate hemostasis and contribute to thrombosis.","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144336839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

JAK2 V617F Mutation Screening for Peripheral Arterial Thrombosis. JAK2 V617F突变在外周动脉血栓形成筛查

IF 3.6 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2025-06-24 DOI: 10.1055/a-2633-7948

Antoine Villa, Clotilde Bravetti, Nicolas Gauthier, Adrien Mirouse, Thibault Couture, Laurent Chiche, Sylvain Choquet, Frédéric Davi, Patrice Cacoub, David Saadoun, Alexandre Le Joncour

引用次数: 0

Bleeding Events and Correlation with Anti-Xa Levels and Therapeutic Nadroparin Dose in Patients with Impaired Renal Function. 肾功能受损患者出血事件与抗xa水平和治疗性纳德帕林剂量的相关性。

IF 3.6 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2025-06-23 DOI: 10.1055/a-2628-2304

Arlette R Cox, Monique M de Maat, Sabine J G M Ahlers, Lian Roovers, Marcel M C Hovens

{"title":"Bleeding Events and Correlation with Anti-Xa Levels and Therapeutic Nadroparin Dose in Patients with Impaired Renal Function.","authors":"Arlette R Cox, Monique M de Maat, Sabine J G M Ahlers, Lian Roovers, Marcel M C Hovens","doi":"10.1055/a-2628-2304","DOIUrl":"https://doi.org/10.1055/a-2628-2304","url":null,"abstract":"Dutch national guidelines for therapeutic treatment with low-molecular-weight heparins (LWMHs) in patients with renal insufficiency recommend dose adjustment based on observed anti-Xa levels. The literature on the relationship between anti-Xa levels and clinical outcome in terms of bleeding events is inconsistent. The primary aim of this study was to investigate the incidence and correlation of bleeding events in relation to anti-Xa levels in patients with impaired renal function, using therapeutic nadroparin according to the national guidelines. The secondary objective was to investigate the correlation between the LMWH dose and bleeding events. This was a retrospective study of patients with impaired renal function treated with therapeutic nadroparin for which anti-Xa levels were monitored. Bleeding and thrombotic events were assessed for each patient. This study included 243 patients, of whom 61 (25%) had a bleeding event. There was no correlation between anti-Xa levels and the occurrence of bleeding. Although there was no difference in renal function, weight, or body mass index (BMI) between patients with or without a bleeding event, the median dose of nadroparin was significantly higher (p < 0.005) in patients with a bleeding event. In conclusion, for this study population, there was a high incidence of bleeding. No correlation was found between anti-Xa levels and the occurrence of a bleeding event, with the majority of anti-Xa levels being subtherapeutic. However, a correlation was found between the dose and the occurrence of a bleeding event. Therefore, it is questionable whether the focus on monitoring anti-Xa levels is a justified method to reduce the risk of a bleeding event.","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144476649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Platelet Function in Patients with Disseminated Intravascular Coagulation: Potential Markers for Improving DIC Diagnosis? 弥散性血管内凝血患者的血小板功能：改善DIC诊断的潜在指标？

IF 3.6 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2025-06-17 DOI: 10.1055/s-0045-1809696

Johanne Duus Petersen, Christine Lodberg Hvas, Julie Brogaard Larsen

{"title":"Platelet Function in Patients with Disseminated Intravascular Coagulation: Potential Markers for Improving DIC Diagnosis?","authors":"Johanne Duus Petersen, Christine Lodberg Hvas, Julie Brogaard Larsen","doi":"10.1055/s-0045-1809696","DOIUrl":"https://doi.org/10.1055/s-0045-1809696","url":null,"abstract":"Disseminated intravascular coagulation (DIC) is a severe complication often associated with critical illness. DIC is characterized by an uncontrolled systemic activation of the hemostatic system, leading to substantial consumption of platelets and coagulation factors. The diagnosis of DIC relies on a combination of clinical findings and laboratory results, yet DIC remains challenging to confirm, especially in early stages. This systematic review investigates the reported associations between platelet function and DIC and evaluates the potential of using platelet function markers as a supplement for DIC diagnosis. PubMed and Embase were searched for relevant literature. Human studies, which included patients with DIC and assessed platelet function using dynamic platelet function assays or soluble markers, were included. In total, 24 studies met the inclusion criteria. We found that DIC patients generally exhibit increased platelet activation in vivo, indicated by elevated plasma levels of soluble markers, while ex vivo platelet aggregation was consistently reduced compared to non-DIC patients and healthy controls; however, not all studies adjusted their results for platelet count. Soluble P-selectin was the most frequently studied plasma marker and was consistently increased in DIC patients; this was most pronounced when adjusted for platelet count. However, there was considerable heterogeneity between studies regarding both study design, patient populations, platelet function assessment, and DIC diagnosis, which complicates the comparison of findings across studies. Future studies accounting for low platelet counts in dynamic function tests are necessary to assess the role of platelet aggregation in relation to DIC.","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144317852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Coagulation Abnormalities Associated with COVID-19: A Narrative Review. 与COVID-19相关的凝血异常：叙述性综述

IF 3.6 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2025-06-17 DOI: 10.1055/a-2619-2485

Massimo Franchini, Daniele Focosi, Pier Mannuccio Mannucci

引用次数: 0

Early Emicizumab Treatment in Acquired Hemophilia A: Impact on Bypassing Agent Use and Length of Hospitalization in an Australian Single-Center Cohort. 早期Emicizumab治疗获得性血友病A：在澳大利亚单中心队列中对旁路药物使用和住院时间的影响

IF 3.6 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2025-06-17 DOI: 10.1055/a-2622-3483

Gianna Pastore, Jeremy Robertson, Sally Campbell, Jane Mason

引用次数: 0

Automation in Platelet Function Testing: Current Challenges and Future Directions. 血小板功能测试自动化：当前挑战和未来方向。

IF 3.6 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2025-06-17 DOI: 10.1055/a-2622-3545

Federico Boggio, Juri A Giannotta, Anna Lecchi

{"title":"Automation in Platelet Function Testing: Current Challenges and Future Directions.","authors":"Federico Boggio, Juri A Giannotta, Anna Lecchi","doi":"10.1055/a-2622-3545","DOIUrl":"10.1055/a-2622-3545","url":null,"abstract":"Platelet function testing is essential for diagnosing and managing platelet function disorders, but faces significant challenges due to complex protocols and variability in results. While light transmission aggregometry remains the gold standard for assessing platelet aggregation, it suffers from several limitations, including labor-intensive protocols, variability in reagents, and poor standardization. Over the decades, improvements such as lumi-aggregometry, which integrates granule secretion testing, and impedance whole-blood aggregometry, which simplifies sample handling, have addressed some of these challenges. Advanced granule secretion assays, including high-performance liquid chromatography and flow cytometry, have further enhanced diagnostic capabilities, although these techniques still depend on specialized expertise and expensive equipment. Recently, significant advancements have been made with automated aggregometers, such as the Sysmex CS series, and high-throughput 96-well plate assays, which improve consistency, throughput, and reproducibility. Nonetheless, further refinement in standardized reagents and consensus-driven protocols is required. Microfluidic technologies, exemplified by systems like the Total Thrombus Analysis System (T-TAS), incorporate physiological shear conditions and real-time thrombus formation assessment, providing enhanced diagnostic insights into platelet behavior. Despite their automation and clinical feasibility, these flow-based systems still require broader validation for routine clinical implementation. Further developments should prioritize integrating complementary assays, enhancing automation, and advancing miniaturization to improve standardization and diagnostic accuracy. Future technologies combined with artificial intelligence-based data interpretation hold the promise to transform platelet diagnostics, enabling personalized patient care. However, achieving widespread clinical adoption requires ongoing collaboration between clinicians, laboratories, industry, and regulatory bodies.","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144161585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Acquired Hemophilia A in a Case of Relapsed Immune Thrombotic Thrombocytopenic Purpura. 复发性免疫性血栓性血小板减少性紫癜一例获得性血友病A。

IF 3.6 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2025-06-17 DOI: 10.1055/a-2622-3585

Antonella Tufano, Ciro Miele, Paolo Conca, Ilenia Calcaterra, Cristina Mazzaccara, Paola Rufolo, Greta Chiarelli, Luigi Jr Valletta, Miriam Mazzone, Raffaele Russo, Guido D'Errico, Matteo Di Minno

引用次数: 0

Neutrophil-Mediated Effects on Hemostasis and Thrombosis: Unraveling Their Complex Interaction in Thrombotic Events. 中性粒细胞介导的止血和血栓形成作用：揭示它们在血栓形成事件中的复杂相互作用。

IF 3.6 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2025-06-03 DOI: 10.1055/a-2605-8019

Saeed Hassani, Alieh Fazeli, Akbar Dorgalaleh, Shadi Tabibian, Jalal Lomei, Maedeh Alipour, Masoumeh Kiani Zadeh, Mahmood Shams

{"title":"Neutrophil-Mediated Effects on Hemostasis and Thrombosis: Unraveling Their Complex Interaction in Thrombotic Events.","authors":"Saeed Hassani, Alieh Fazeli, Akbar Dorgalaleh, Shadi Tabibian, Jalal Lomei, Maedeh Alipour, Masoumeh Kiani Zadeh, Mahmood Shams","doi":"10.1055/a-2605-8019","DOIUrl":"https://doi.org/10.1055/a-2605-8019","url":null,"abstract":"Neutrophils are astonishing cells involved in nonspecific immunity, especially against bacterial and fungal infections. Their half-life is short, but despite their important role in nonspecific immunity, they defend the host even after their death by providing secondary structures such as neutrophil extracellular traps (NETs). NETs are a network comprising DNA, histones, and proteins, including elastase, cathepsin G, and myeloperoxidase. In this context, in addition to their primary role in hemostasis, they also play a role in thrombosis, an area that has received less attention. Nonetheless, NETs can promote both venous and arterial thrombus formation (immuno-thrombosis), by their effects on primary and secondary hemostasis; their participation in thrombus formation includes the release of microparticles and components of the inflammasome. Neutrophils in interaction with other cells including platelets can further contribute to thrombosis. Activated platelets can capture neutrophil-derived microparticles containing tissue factor (TF), leading to TF accumulation and increased fibrin deposition. Furthermore, neutrophil inflammasomes as a regulator of the generation of IL-1 family proteins have been shown to augment thrombosis formation in response to hypoxia. Overall, understanding the complex and reciprocal effects of neutrophils with other hemostasis-related cells and components provides important insights into hemostatic mechanisms, and this may open avenues in medical research and potential therapeutic interventions.","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144216763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeting Neutrophil Extracellular Traps: A New Strategy for the Treatment of Acute Ischemic Stroke Based on Thrombolysis Resistance. 靶向中性粒细胞胞外陷阱：基于溶栓抵抗治疗急性缺血性脑卒中的新策略。

IF 3.6 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2025-06-03 DOI: 10.1055/a-2609-3457

Genquan Huang, Hao Wu, Bintong Lin, Dezhi Deng, Yuan Liu, Juan Qu, Junjie Xu, Baoxiang Wang

引用次数: 0